Priya Alexander

So they have said semaglutide, which people would know as Ozempic, should be considered for weight management in people who have established heart disease to reduce their risk.

Had a heart attack, yes.

They've said a GLP-1 with proven cardiovascular benefits, so that includes semaglutide or ozempic, liraglutide or tazapatide, which people would know as Monjaro, should be considered in adults with type 2 diabetes to reduce heart disease.

Yes, you're automatically high risk.

And then for people, adults living with heart failure...

With their ejection fraction preserved, so you're still able to contract and get good blood flow out of the heart, they have suggested considering Ozempic or Monjaro semaglutide or Tazapatide to improve someone's symptoms and their functional capacity, so ability to exercise.

But I perused this with my GP hat on.

Well, sometimes.

It's hard to take it off, to be honest.

But the guideline, well, I found the document very useful because it really openly acknowledged things like weight stigma, inequities in the healthcare system.

It also talked about the complexities of weight and the kind of relationship between excess fat tissue and how it impacts cardiac function.

It was a really clear linking of these things.

And whilst it's really good guidance, Norman...

I thought some of this is still not implementable because of equity issues.

It's still not on the PBS.

Yes.

So access equity here is a real problem.

So whilst it's nice to have the guidance, I know lots of patients of mine still won't be able to access it.

Yeah, which just widens the gap further and further.

Good news on RSV.